{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:00:17Z","timestamp":1794488417065,"version":"4.9.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.jval.2015.02.016","type":"journal-article","created":{"date-parts":[[2015,5,16]],"date-time":"2015-05-16T03:09:30Z","timestamp":1431745770000},"page":"425-431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Modeling Health State Utility Values in Ankylosing Spondylitis: Comparisons of Direct and Indirect Methods"],"prefix":"10.1016","volume":"18","author":[{"given":"Allan","family":"Wailoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceri","family":"Philips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Brophy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-7311","authenticated-orcid":false,"given":"Stefan","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2015.02.016_bib1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s40273-013-0069-y","article-title":"Good practice guidelines for the use of statistical regression models in economic evaluations","volume":"31","author":"Kearns","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2015.02.016_bib2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MAJ.0b013e3182514059","article-title":"Management of comorbidities in ankylosing spondylitis","volume":"343","author":"Rosenbaum","year":"2012","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jval.2015.02.016_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/bmj.38954.689583.DE","article-title":"Diagnosis and management of ankylosing spondylitis","volume":"16","author":"McVeigh","year":"2006","journal-title":"BMJ"},{"issue":"Suppl 3","key":"10.1016\/j.jval.2015.02.016_bib4","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1136\/ard.61.suppl_3.iii8","article-title":"Ankylosing spondylitis: an overview","volume":"61","author":"Sieper","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2015.02.016_bib5","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jval.2015.02.016_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/rheumatology\/34.8.793","article-title":"Bath ankylosing-spondylitis functional index","volume":"34","author":"Calin","year":"1995","journal-title":"Br J Rheumatol"},{"issue":"Suppl. II","key":"10.1016\/j.jval.2015.02.016_bib7","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2015.02.016_bib8","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/rheumatology\/kem031","article-title":"Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom","volume":"46","author":"Botteman","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.jval.2015.02.016_bib9","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/rheumatology\/kem133","article-title":"The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK","volume":"46","author":"Ara","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.jval.2015.02.016_bib10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1017\/S0266462307070432","article-title":"Comparison of the cost effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials","volume":"23","author":"Kobelt","year":"2007","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.jval.2015.02.016_bib11","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/keq222","article-title":"Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany","volume":"49","author":"Neilsen","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.jval.2015.02.016_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s40273-013-0049-2","article-title":"Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal","volume":"31","author":"Armstrong","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2015.02.016_bib13","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/rheumatology\/keh271","article-title":"The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade)","volume":"43","author":"Kobelt","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.jval.2015.02.016_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1477-7525-10-151","article-title":"Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients","volume":"10","author":"Kim","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2015.02.016_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1477-7525-8-54","article-title":"Mapping of the EQ-5D index from clinical outcome measures and demographic variables in patients with coronary heart disease","volume":"8","author":"Goldsmith","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2015.02.016_bib16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jval.2012.12.005","article-title":"Mapping EQ-5D utility scores from the Incontinence Quality of Life Questionnaire among patients with neurogenic and idiopathic overactive bladder","volume":"16","author":"Kay","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.02.016_bib17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/0272989X13500720","article-title":"A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes","volume":"34","author":"Hernandez Alava","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2015.02.016_bib18","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/rheumatology\/kes400","article-title":"The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis","volume":"52","author":"Hernandez Alava","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.jval.2015.02.016_bib19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jval.2011.12.014","article-title":"Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D health state utility values","volume":"15","author":"Hernandez Alava","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.02.016_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1477-7525-12-37","article-title":"Modelling the relationship between the WOMAC Osteoarthritis Index and EQ-5D","volume":"12","author":"Wailoo","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2015.02.016_bib21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/1471-2474-11-197","article-title":"Protocol for a population-based Ankylosing Spondylitis (PAS) cohort in Wales","volume":"11","author":"Atkinson","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jval.2015.02.016_bib22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/0272989X05284108","article-title":"Estimating the association between SF-12 responses and EQ-5D utility values by response mapping","volume":"26","author":"Gray","year":"2006","journal-title":"Med Decis Making"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515018537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515018537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:32:53Z","timestamp":1748392373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301515018537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1098301515018537"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2015.02.016","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling Health State Utility Values in Ankylosing Spondylitis: Comparisons of Direct and Indirect Methods","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2015.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}